IBI3042 is named as an intervention in 2 current clinical trials in our China register. 1 is recruiting patients now. All registered phases are Phase 1. The sponsor with the most trials is Innovent Biologics (Suzhou) Co. Ltd (1). The most-studied condition is Overweight.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
IBI3042 Study in Healthy Participants and Overweight or Obese Participants
NCT07793019 · ClinicalTrials.gov ↗ · Overweight, Healthy Participants, Obesity
|
Phase 1 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | China |
|
An Exploratory Study of Single-Dose and Multiple-Doses IBI3042 in Healthy, Overweight, or Obese Participants
NCT07802899 · ClinicalTrials.gov ↗ · Overweight, Obesity, Heathy Participants
|
Phase 1 | Not yet open | Hongwei Jiang | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Innovent Biologics (Suzhou) Co. Ltd. | 1 |
| Hongwei Jiang | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name IBI3042 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Innovent Biologics (Suzhou) Co. Ltd (1) and Hongwei Jiang (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how IBI3042 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how IBI3042 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists IBI3042 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.